ABBV and MRK Related Headlines
Go Back- Trump to unveil more discounted prescription drug options - CNBC
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
- Bernstein on US Pharma and Biotech: Who might buy whom?
- RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
- Barclays launches U.S. biopharma coverage with four preferred picks
- This U.S. biotech stock is Bernstein's Top Pick for 2026
- Revolution Medicines stock rises on Merck acquisition talks
- Merck (MRK) in Talks to buy Revolution Medicines (RVMD) - FT
- Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe
- Trump to announce prescription drug price agreements
- Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
- Trump demands pharma CEOs lower drug prices within 60 days
- Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
- Lawmakers push to ban direct-to-consumer drug advertising, WSJ reports
